BiomimX S.r.l. is a pioneer in Organ-on-a-Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and development. BiomimX proprietary platform integrates microfluidics, 3D cell culture, live human cells, and mechanical stimuli to develop “Beating Organs-on-a-Chip”. These systems recapitulate clinically relevant aspects of human physiology and pathology with unprecedented precision and predictability. Pharma R&D is an area where animal models continue to fall short due to lack of translatability and a lack of relevant models. Regulatory agencies worldwide are now moving forward to encourage biopharma’s use of more predictive, human-relevant non-animal models. BiomimX is poised to be a leader in this space and has gained early traction with industry.
In PHOENIX, BiomimX contributes to the development of the next-generation OoC platforms, μHeart for cardiac tissues and μNMC for neuro-muscular circuits. BiomimX will indeed brings its 3DMECH technology to the table, which provides mechanical stimulation to the cultured microtissues, to be integrated with the other PHOENIX’s core technologies. BiomimX will perform functional testing across the platform development pipeline (from low-throughput, PDMS-based initial prototypes to the final PDMS-free, plate-format, automation-compatible product) focusing on pharmacological campaigns to validate µHeart cardiac model for cardiotoxicity screening. In addition, BiomimX will develop a novel mechanical actuator, uBox4, to enable controlled mechanical stimulation to in PHOENIX platforms. BiomimX will also contribute in stakeholder engagement for PHOENIX products and dissemination activities.
Main contributions and activities:
Paola Occhetta – CEO
Roberta Visone – R&D Science Leader
Stefano Piazza – R&D Product Engineer
Caterina Pernici – R&D Product Engineer
